Comparing Hillstream Biopharma (CNTN) & Its Peers

Hillstream Biopharma (NASDAQ:CNTN) is one of 226 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Hillstream Biopharma to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.

Risk & Volatility

Hillstream Biopharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Hillstream Biopharma’s rivals have a beta of 12.16, meaning that their average stock price is 1,116% more volatile than the S&P 500.

Institutional and Insider Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Hillstream Biopharma and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hillstream Biopharma	N/A	-$35.92 million	-0.81
Hillstream Biopharma Competitors	$335.36 million	-$27.03 million	-4.46

Hillstream Biopharma’s rivals have higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Hillstream Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-35.59%	-27.05%
Hillstream Biopharma Competitors	-4,803.12%	-250.26%	-48.16%

Analyst Ratings

This is a summary of current recommendations and price targets for Hillstream Biopharma and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Hillstream Biopharma Competitors	2228	2461	4375	69	2.25

As a group, “Pharmaceutical Preparations” companies have a potential upside of 119.66%. Given Hillstream Biopharma’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Hillstream Biopharma has less favorable growth aspects than its rivals.

Summary

Hillstream Biopharma rivals beat Hillstream Biopharma on 9 of the 13 factors compared.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.